REFERENCES

1. NICE Clinical Knowledge Summaries for the common cold, available at:https://cks.nice.org.uk/common-cold#!backgroundSub:2.Last accessed 16.08.16.

2. Worral G. Common cold. Canadian family physician 2007;53(10):1735-1736.

3. Simasek and Blandino D. Treatment of the common cold. American family physician 2007;75(4):515-520.

4. Eccles R. Understanding the symptoms of the common cold and influenza. The Lancet infectious diseases 2005;5(11):718-725

5. Hayden F, Diamond L, Wood PB, Sorts DC, Wrecker MT. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine 1996;125(2):89-97.

6. Sinusitis (sinus pain). NHS. Available online at https://www.nhs.uk/conditions/sinusitis-sinus-infection/ Accessed 04/07/19.

7. Graf P, Eccles R, Chen S. Efficacy and safety of intranasal xylometazoline and ipratropium in patients with common cold. Expert Opin Pharmacother 2009;10(5):889-908.

8. Eccles R, Pederson A, Regberg D, Tulento H, Borum P, Stjärne P. Efficacy and safety of topical combinations of ipratropium and xylometazoline for the treatment of symptoms of runny nose and nasal congestion associated with acute upper respiratory tract infection. Am J Rhinol 2007;21:40-45.

9. Summary of Product Characteristics. Otrivine Extra Dual Relief Nasal Spray. Available at: https://www.medicines.org.uk/emc/product/10022. Last updated January 2019.